Statements (17)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Gilead_Sciences
|
| gptkbp:CEO |
Scott Clarke
|
| gptkbp:collaboratesWith |
gptkb:Gilead_Sciences
|
| gptkbp:focus |
gptkb:cancer
immunotherapy |
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tizona Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
TTC-310
TTC-352 |
| gptkbp:specialty |
immune checkpoint inhibitors
targeted immunotherapies |
| gptkbp:website |
https://tizonatx.com/
|
| gptkbp:bfsParent |
gptkb:South_San_Francisco,_California,_USA
|
| gptkbp:bfsLayer |
7
|